SCHEMBL20013482

CCCCC1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](Cc2cn(CCCCCNC(=O)CCC(=O)Oc3c(C)c(C)c4c(c3C)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O4)nn2)C(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CN)C(=O)N[C@@H](CC(C)C)C(=O)N2C[C@H](O)C[C@H]2C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCc2csc3ccccc23)C(=O)N1C

nearest known ligand 0.51

Predicted protein targets (top 6)

	gene	UniProt	supporting neighbours	confidence
▸	CD274	Q9NZQ7	8/20	0.51

▸	PDCD1	Q15116	6/20	0.48

▸	NECTIN4	Q96NY8	3/20	0.43

▸	TNFRSF9	Q07011	4/20	0.43

▸	PRLHR	P49683	4/20	0.41

▸	CIB1	Q99828	2/20	0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL20009672	0.98	CD274 (0.52)	CD274PDCD1NECTIN4TNFRSF9PRLHR
SCHEMBL17751953	0.92	CD274 (0.51)	CD274PDCD1NECTIN4TNFRSF9PRLHR
SCHEMBL22199641	0.88	CD274 (0.52)	CD274PDCD1NECTIN4TNFRSF9CIB1
SCHEMBL22199653	0.86	CD274 (0.47)	CD274PDCD1NECTIN4TNFRSF9PRLHR
SCHEMBL20013291	0.86	CD274 (0.59)	CD274PDCD1NECTIN4TNFRSF9PRLHR
SCHEMBL20013175	0.86	CD274 (0.45)	CD274PDCD1NECTIN4TNFRSF9PRLHR
SCHEMBL22199763	0.86	CD274 (0.47)	CD274PDCD1NECTIN4TNFRSF9CIB1
SCHEMBL22199764	0.86	CD274 (0.44)	CD274PDCD1NECTIN4TNFRSF9PRLHR
SCHEMBL22199734	0.85	CD274 (0.47)	CD274PDCD1NECTIN4TNFRSF9PRLHR
SCHEMBL24503315	0.85	CD274 (0.42)	CD274PDCD1NECTIN4TNFRSF9PRLHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-10633419-B2	Immunomodulators	BRISTOL-MYERS SQUIBB COMPANY (US)	2020-04-28	—	—	US	disclosed
US-20180086793-A1	IMMUNOMODULATORS	BRISTOL MYERS SQUIBB CO (US)	2018-03-29	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-10633419-B2	Immunomodulators	CD74, ICOS, HAVCR2	CD274 36/4885PDCD1 79/4885NECTIN4 266/4885
US-20180086793-A1	IMMUNOMODULATORS	CD74, ICOS, HAVCR2	CD274 36/4885PDCD1 79/4885NECTIN4 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.